Delivered by Hiroko Nishimoto, JPMA Liaison Executive, IFPMA Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to provide our perspective on dementia. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations worldwide. IFPMA highly commends the WHO Secretariat for its vision...
Read moreDelivered by Cyntia Genolet, Manager, Regulatory and Health Policy Progress toward health improvement will not be achievable without a consistent and constant fight against falsified medicines. Falsified medicines deliberately and deceitfully attempt to pass themselves off as genuine approved medicines. They represent a serious threat to patients, and undermine the full spectrum of legitimate medicines...
Read moreDelivered by Grega Kumer, Manager, Legal Issues Thank you Mr. Chairman, IFPMA and its members appreciate WHO efforts to increase awareness amongst Member States about the significant public health implications related to implementation of the Nagoya Protocol. We fully support the objectives of the Convention on Biological Diversity and of the Nagoya Protocol, including facilitating...
Read moreDelivered by Laetitia Bigger, Director, Vaccines Policy IFPMA welcomes WHO’s efforts in developing a framework to mitigate or avert shortages and resulting stockouts. Together with our partners, we are united by a common purpose to save lives, improve health, and ensure long-term prosperity. We are committed to provide a reliable supply of medicines and vaccines...
Read moreIFPMA welcomes the “Paragraph 6” amendment to the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that entered into force yesterday. The amendment makes permanent previous waivers allowing countries with insufficient or no manufacturing capacity to import medicines from manufacturers in certain circumstances. IFPMA has supported the 30 August 2003...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) supports the aims of a newly formed public-private partnership to accelerate research and development of vaccines for emerging infectious diseases. The Coalition for Epidemic Preparedness Innovation (CEPI) is a direct response to calls from four independent expert reports into the Ebola epidemic for a new system...
Read moreWe welcome the Ministerial Statement from the OECD Health Committee, which seeks to address many important issues for health systems in OECD countries. Reducing waste and low-value care, to facilitate investment in the interventions that bring the most benefit to patients, is critical to the quality and sustainability of healthcare across OECD countries. This evolution...
Read more22 Biopharma Companies Partner and Launch First-of-its-kind Global Initiative to Address Rise of Non-Communicable Diseases Global, multi-stakeholder collaboration, called Access Accelerated, to be delivered in partnership with World Bank Group and Union for International Cancer Control (UICC) Initial three-year commitment will catalyze, develop, measure and replicate sustainable programs in low and lower-middle income countries...
Read moreBiopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical trial data in a manner that is consistent with the following principles: Safeguarding the privacy of patients, respecting the integrity of national regulatory systems, and maintaining incentives for investment in biomedical research.
Read moreGeneva, 2 December 2016 – On 29 November 2016, Thomas B. Cueni was appointed Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the organization representing biopharmaceutical companies as well as national and regional associations across the world. He will succeed Eduardo Pisani who recently announced his departure after seven years...
Read moreIan C. Read, Chairman of the Board and Chief Executive Officer, Pfizer, takes over as President of IFPMA from Dr Stefan Oschmann, Chairman of the Executive Board and CEO, Merck KGaA, Darmstadt, Germany. New President to foster innovative health ecosystems and expand partnerships and focus on people/patient-centric and systemic approaches to ensure health through the...
Read more